Day Two
Wednesday 1st March 2023
8:25 am Chair’s Opening Remarks
8:30 am Panel Discussion: Focusing & Benchmarking the Antigen-Specific Immune Tolerance Space
Synopsis
- What Do the Next 12 Months Look Like?
- Exploring safety considerations: Is there risk of activating a counter-regulatory immune response?
- Discussing the most promising therapeutics in the landscape – what readouts do we expect in 2023?
- Where is the field with novel technologies, and what must we understand to move forward?
Exploring Effective Model Systems that Reflect the In-Human Condition to Bridge the Translational Gap
9:00 am Bridging the Transition Between Mouse Models to the Patient: Facilitating the Translational Stage from Preclinical to In-Human Studies
Synopsis
- Exploring in-vitro models with human cells and humanized mouse models
- Developing a mechanistic understanding of how a human immune system responds in comparison to a mouse immune system
Investigating Clinical Endpoints & Determinants of Efficacy for Tolerance Induction Clinical Trial Design
9:30 am Visualizing Immune Tolerance Induction: Exploring Immune Tolerance Biomarkers for Celiac Disease
Synopsis
- Looking at immune tolerance in people using multiple different techniques
- How do visualize immune tolerance using biomarkers?
- How far can you interpret the data as tolerance induction?
10:00 am Generating Mechanistic Proof-Of-Concept for Antigen-Specific Tolerization
Synopsis
- Challenges in designing biomarker programs for clinical trials in cell therapy based tolerization
- Dealing with the challenges of patient heterogeneity and responsiveness to therapy
- Explaining the need for multiple parameters to understand the mechanisms of tolerization
10:30 am Morning Break
11:00 am Single Cell Transcriptomics of Antigen-Specific CD4 T-Cells to Identify Biomarkers of Imotope™ Treatment & Impact on Pathogenic CD4 T-Cells in Patients With Type 1 Diabetes
Synopsis
- Highlighting the biomarker interim analyses of phase 2 IMPACT trial in type-diabetes
- Using single cell transcriptomics to analyse antigen-specific CD4 cells
Honing the Understanding of Immune Tolerance to Illuminate Strategies for Successful Tolerization Therapeutics for Autoimmune Diseases
11:30 am Panel Discussion: Selecting an Antigen – Determining What Makes a ‘Good’ Antigen
Synopsis
- What is the ideal profile of a good antigen?
- What are the technical considerations?
- Which antigens drive epitope heterogeneity in diseases?
12:10 pm Lunch & Networking
1:10 pm Mechanisms & Clinical Translation of Antigen-Encapsulating PLGA Nanoparticles for Tolerance Therapy of T Cell-Mediated Diseases
Synopsis
- Ag-PLGA tolerance induction recapitulates how tolerance is induced in the hematopoietic compartment via uptake of apoptotic debris by scavenger receptors on splenic and liver APCs
- Ag-PLGA tolerance requires activation of the cGAS/STING pathway
- Ag-PLGA tolerance is dependent of induction of IL-10 producing Tregs
- Ag-PLGA tolerance has been demonstrated to be effective in a phase 1/2a clinical trial in celiac disease
1:40 pm Roundtables: Exploring Different Approaches to Antigen-Specific Immune Tolerance: Attacking the Problem from Different Angles
Synopsis
This session will facilitate in-depth discussion between participants in an informal environment to explore different approaches to antigen-specific immune tolerance. Join a table and discuss your chosen topic then feedback to the chair and group
2:00 pm Using CAR-Treg Cells in the Setting of Refractory Systemic Lupus Erthematosus
Synopsis
- Developing CAR-Tregs in the experimental or pre-clinical setting for autoimmune disease